Under LOI: Tech-2605: High-Growth ISO-accredited Bioanalytical Laboratory Serving Pharma, Biopharma & Peptide Markets

Lab Scientist

ISO-17025 accredited bioanalytical laboratory serving pharmaceutical, biopharma, and peptide markets, offering USP, EP, and JP raw material testing, biomolecule characterization, chromatography, mass spectrometry, microbiological analysis, PCR, and assay development. The company has recently entered a period of strong revenue acceleration, with visible momentum, expanding client demand, and projected revenue of ~$1M in 2026. This is a scalable, turnkey laboratory platform with skilled staff and an actively involved Ph. D.-trained founder, and well-positioned for growth under a strategic partner with pharma or life sciences relationships.

Overview

The Company is an ISO-17025 accredited, full-service bioanalytical laboratory specializing in the characterization and testing of pharmaceutical and biological products, including raw material analysis, biomolecule characterization, and assay development. The laboratory serves pharmaceutical, biopharma, and nutraceutical clients, with accelerating demand from the peptide and food supplement sectors.

The business has recently turned a corner, achieving strong and sustained revenue growth over the past seven months and entering 2026 with robust momentum and expanding client demand.

Core Capabilities

• Raw material testing compliant with USP, European Pharmacopeia (EP), and Japanese Pharmacopeia (JP) standards

• Biomolecule characterization, including vaccines and peptides

• Chromatography and mass spectrometry

• Microbiological analysis, PCR, and endotoxin testing

• Pharmaceutical method development and biological assay development

• Support for product and formulation development

The ability to operate seamlessly across USP, EP, and JP methods makes the laboratory particularly attractive to multinational clients operating across multiple regulatory regimes, while its responsiveness and technical depth also appeal to emerging and mid-sized companies.

Market Positioning & Differentiation

• One of a limited number of bioanalytical labs comfortable working across both conventional pharma and biopharma products

• Increasing demand driven by peptide testing and biologics

• Highly versatile platform suitable for strategic expansion under a larger commercial or operational umbrella

• Turn-key laboratory with skilled staff and established workflows

Financial Highlights

• 2025 Revenue: $461,000

• 2025 SDE: ~$180,000

• 2026 Projected Revenue: ~$1,000,000

• 2026 Projected SDE: ~$400,000

Revenue acceleration is well supported by recent performance:

• Average monthly revenue (last 6 months): ~$66,000

• January 2026 revenue: ~$85,000

• Strong inbound inquiry volume continuing into 2026

Transaction Overview

• Offering: 75% equity stake

• Asking Price: $400,000 (for 75%)

• Structure: Strategic partnership with majority ownership

The transaction provides a strategic buyer with immediate control of a high-capability laboratory while retaining a highly experienced Ph.D. scientist owner / laboratory director who remains invested in the Company’s long-term success.

Growth Opportunity

With enhanced commercial reach, broader pharma relationships, and modest growth capital, the laboratory is well positioned to scale meaningfully. The current platform supports expansion into:

• Higher-volume peptide and biologics testing

• Deeper pharma and biopharma client penetration

• Expanded development and validation services

The seller believes the business can scale to multi-million-dollar revenue levels with the right strategic partner.

Management

The laboratory is led by a Ph.D. scientist owner with deep expertise in analytical chemistry, mass spectrometry, pharmaceutical and biopharma quality testing, and assay development. His background includes experience spanning early-stage analysis through large-scale manufacturing environments, providing a rare blend of technical depth and real-world scale-up experience.

Strategic Rationale

This opportunity is well-suited for:

• Strategic laboratory platforms seeking expanded bioanalytical capabilities

• Pharma, biopharma, or CDMO organizations looking to internalize or extend testing capacity

• Investors seeking a recently inflected, high-capability lab with visible growth momentum